Lung Cancer

MOGA welcomes pemetrexed de-restriction for NSCLC

The PBS de-restriction of pemetrexed to allow it to be used in the first-line treatment of NSCLC has been welcome by the Medical Oncology Group of Australia. Chair Professor Chris Karapetis said the changing of the listing for pemetrexed on the PBS from streamlined to allow it to be prescribed unrestricted as part of first ...

Already a member?

Login to keep reading.

© 2021 the limbic